Lexeo Therapeutics, Inc. Earnings Per Share (Basic)
Lexeo Therapeutics, Inc. (LXEO) reported Earnings Per Share (Basic) of -$0.30 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Lexeo Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.30.
- Lexeo Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.25.
- Lexeo Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.27.
- Lexeo Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.33.
- Lexeo Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$1.86.
- Lexeo Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$3.09.
- Lexeo Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$12.40.
- Lexeo Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$36.36.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.30 10-Q · filed 2026-08-12 | -$0.55 10-Q · filed 2026-08-12 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.15 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2026-03-31 | -$0.25 10-Q · filed 2026-05-11 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.84 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-12-31 | -$0.27 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.86 10-K · filed 2026-03-30 |
| 2025-09-30 | -$0.33 10-Q · filed 2025-11-05 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$1.72 10-Q · filed 2025-11-05 | -$2.46 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-06-30 | -$0.60 10-Q · filed 2026-08-12 | -$1.53 10-Q · filed 2026-08-12 | -$2.31 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.20 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2025-03-31 | -$0.99 10-Q · filed 2026-05-11 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$2.66 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$3.31 derived: net income ÷ weighted average shares · filed 2026-08-12 |
| 2024-12-31 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-03-30 | -$3.09 10-K · filed 2026-03-30 |
| 2024-09-30 | -$0.89 10-Q · filed 2025-11-05 | -$1.54 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$2.31 10-Q · filed 2025-11-05 | -$3.13 derived: net income ÷ weighted average shares · filed 2025-11-05 |
| 2024-06-30 | -$0.64 10-Q · filed 2025-08-14 | -$1.41 10-Q · filed 2025-08-14 | -$2.21 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$3.90 derived: net income ÷ weighted average shares · filed 2025-11-05 |
| 2024-03-31 | -$0.77 10-Q · filed 2025-05-12 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$3.64 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$5.81 derived: net income ÷ weighted average shares · filed 2025-11-05 |
| 2023-12-31 | -$0.86 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$3.77 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$7.23 derived: net income ÷ weighted average shares · filed 2025-03-24 | -$12.40 10-K · filed 2025-03-24 |
| 2023-09-30 | -$12.36 10-Q · filed 2024-11-13 | -$20.67 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$32.24 10-Q · filed 2024-11-13 | -$41.09 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-06-30 | -$8.30 10-Q · filed 2024-08-12 | -$19.87 10-Q · filed 2024-08-12 | -$28.72 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$39.11 derived: net income ÷ weighted average shares · filed 2024-11-13 |
| 2023-03-31 | -$11.58 10-Q · filed 2024-05-09 | -$20.42 derived: net income ÷ weighted average shares · filed 2024-11-13 | -$30.80 derived: net income ÷ weighted average shares · filed 2024-11-13 | |
| 2022-12-31 | -$8.86 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$19.24 derived: net income ÷ weighted average shares · filed 2024-03-11 | -$36.36 10-K · filed 2024-03-11 | |
| 2022-09-30 | -$10.38 10-Q · filed 2023-12-11 | -$27.50 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |